Literature DB >> 21771036

Expression of 'drugable' tyrosine kinase receptors in malignant peripheral nerve sheath tumour: potential molecular therapeutic targets for a chemoresistant cancer.

Keila E Torres, Jun Liu, Eric Young, Kai-Lieh Huang, Markus Ghadimi, Kristelle Lusby, Alexander J Lazar, Dina Lev.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21771036      PMCID： PMC4532392          DOI： 10.1111/j.1365-2559.2011.03867.x

Source DB:  PubMed          Journal:  Histopathology        ISSN： 0309-0167            Impact factor:   5.087


× No keyword cloud information.
  7 in total

Review 1.  Tyrosine kinases as targets in cancer therapy - successes and failures.

Authors:  Peter Traxler
Journal:  Expert Opin Ther Targets       Date:  2003-04       Impact factor: 6.902

Review 2.  The emergence of resistance to targeted cancer therapeutics.

Authors:  Ingo K Mellinghoff; Charles L Sawyers
Journal:  Pharmacogenomics       Date:  2002-09       Impact factor: 2.533

Review 3.  Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways.

Authors:  Daniela Katz; Alexander Lazar; Dina Lev
Journal:  Expert Rev Mol Med       Date:  2009-10-19       Impact factor: 5.600

4.  MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Authors:  Jeffrey A Engelman; Kreshnik Zejnullahu; Tetsuya Mitsudomi; Youngchul Song; Courtney Hyland; Joon Oh Park; Neal Lindeman; Christopher-Michael Gale; Xiaojun Zhao; James Christensen; Takayuki Kosaka; Alison J Holmes; Andrew M Rogers; Federico Cappuzzo; Tony Mok; Charles Lee; Bruce E Johnson; Lewis C Cantley; Pasi A Jänne
Journal:  Science       Date:  2007-04-26       Impact factor: 47.728

5.  Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome.

Authors:  Changye Zou; Kerrington D Smith; Jun Liu; Guy Lahat; Sarah Myers; Wei-Lien Wang; Wei Zhang; Ian E McCutcheon; John M Slopis; Alexander J Lazar; Raphael E Pollock; Dina Lev
Journal:  Ann Surg       Date:  2009-06       Impact factor: 12.969

6.  EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy.

Authors:  Nikola Holtkamp; Elke Malzer; Jan Zietsch; Ali Fuat Okuducu; Jana Mucha; Christian Mawrin; Victor-F Mautner; Hans-Ulrich Schildhaus; Andreas von Deimling
Journal:  Neuro Oncol       Date:  2008-07-23       Impact factor: 12.300

7.  Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.

Authors:  Changye Y Zou; Kerrington D Smith; Quan-Sheng Zhu; Jun Liu; Ian E McCutcheon; John M Slopis; Funda Meric-Bernstam; Zhenghong Peng; William G Bornmann; Gordon B Mills; Alexander J Lazar; Raphael E Pollock; Dina Lev
Journal:  Mol Cancer Ther       Date:  2009-05-05       Impact factor: 6.261
  7 in total
  5 in total

1.  Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs.

Authors:  Parag P Patwardhan; Oliver Surriga; Michael J Beckman; Elisa de Stanchina; Ronald P Dematteo; William D Tap; Gary K Schwartz
Journal:  Clin Cancer Res       Date:  2014-04-09       Impact factor: 12.531

2.  Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.

Authors:  Keila E Torres; Quan-Sheng Zhu; Katelynn Bill; Gonzalo Lopez; Markus P Ghadimi; Xianbiao Xie; Eric D Young; Juehui Liu; Theresa Nguyen; Svetlana Bolshakov; Roman Belousov; Suizhau Wang; Guy Lahat; Jun Liu; Belinda Hernandez; Alexander J Lazar; Dina Lev
Journal:  Clin Cancer Res       Date:  2011-05-03       Impact factor: 12.531

3.  Treatment of neurofibromatosis type 1.

Authors:  Caterina Sabatini; Donatella Milani; Francesca Menni; Gianluca Tadini; Susanna Esposito
Journal:  Curr Treat Options Neurol       Date:  2015-06       Impact factor: 3.598

4.  Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors.

Authors:  Markus P Ghadimi; Gonzalo Lopez; Keila E Torres; Roman Belousov; Eric D Young; Jeffery Liu; Kari J Brewer; Aviad Hoffman; Kristelle Lusby; Alexander J Lazar; Raphael E Pollock; Dina Lev
Journal:  Mol Cancer Ther       Date:  2012-07-30       Impact factor: 6.261

5.  AXL Inhibition Enhances MEK Inhibitor Sensitivity in Malignant Peripheral Nerve Sheath Tumors.

Authors:  Sharon M Landers; Angela D Bhalla; XiaoYan Ma; Kristelle Lusby; Davis Ingram; Ghadah Al Sannaa; Wei-Lien Wang; Alexander J Lazar; Keila E Torres
Journal:  J Cancer Sci Clin Ther       Date:  2020-10-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.